The abstract is read at the publisher; the summary is JClub's.
In syngeneic tumor models, genetic inhibition of ZDHHC15 disrupts CD155 S-acylation, leading to CD155 degradation and enhanced CD8+ T cell infiltration that suppresses tumor growth.
- Why it matters: CD155 is frequently upregulated in malignancies and contributes to immune evasion, but the posttranslational control of its stability and immunosuppressive activity was unclear.
- What they did: Using chemical reporters, the study shows CD155 is S-acylated at three cytoplasmic cysteines by ZDHHC15 and deacylated by PPT1/APT1, which protects it from lysosomal degradation.
- The result: S-acylation sustains CD155 interaction with Sprouty2 and oncogenic ERK signaling; blocking ZDHHC15 increases CD155 degradation and anti-tumor immunity, and abemaciclib promotes this via PPT1 upregulation and lysosome biogenesis.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.